Moderna Inc (NASDAQ: MRNA) is looking to scale up the production of its mRNA vaccines and therapeutics on a global level. The firm this morning announced a significant expansion within Asian markets, following the news last night that the company is expanding its operations in Spain.
In terms of its operations in Spain, the firm last night indicated it has expanded a long-term collaboration agreement that was previously in place. The collaboration, which is with its partner Laboratorios Farmacéuticos Rovi, S.A, will see the expansion of current capacity for the manufacturing of Moderna’s products within the country.
Presently, Rovi operates several facilities near Madrid where Moderna’s vaccines are produced. The new arrangement expands the working agreement between the two firms for a period of ten years. Presently, the arrangement will see the scaling of the manufacturing of COVID-19 vaccines, while in the future the agreement will facilitate the production of future mRNA vaccine candidates. Included in the arrangement is a series of investments that are said to support the purchase of additional equipment for production lines.
Products produced at the facility are currently used within countries outside of the United States.
In terms of Asian markets, the company this morning announced that it will be establishing new subsidiaries within Hong Kong, Taiwan, Singapore and Malaysia which will be used to “support the delivery of mRNA vaccines and therapeutics.” The expansion of the commercial network follows the company scaling the production of its current vaccine, as well as future mRNA vaccines and therapeutics. The drive to expand within Asian markets is a result of the region reportedly bearing “the highest burden of infectious diseases.”
Moderna’s portfolio currently consists of 40 development programs. 25 of these programs are currently in varying stages of clinical trials.
Moderna last traded at $151.12 on the Nasdaq.
Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.